These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 34288380)
21. A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders. Nogami K; Matsumoto T; Sasai K; Ogiwara K; Arai N; Shima M Br J Haematol; 2019 Nov; 187(4):518-529. PubMed ID: 31335970 [TBL] [Abstract][Full Text] [Related]
22. Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury. Zentai C; van der Meijden PE; Braunschweig T; Hueck N; Honickel M; Spronk HM; Rossaint R; Grottke O Anesth Analg; 2016 Jul; 123(1):38-48. PubMed ID: 27192476 [TBL] [Abstract][Full Text] [Related]
23. Preparation and the hemostatic property study of porous gelatin microspheres both in vitro and in vivo. Li L; Du Y; Yin Z; Li L; Peng H; Zheng H; Yang A; Li H; Lv G Colloids Surf B Biointerfaces; 2020 Mar; 187():110641. PubMed ID: 31759778 [TBL] [Abstract][Full Text] [Related]
25. Synergism of red blood cells and tranexamic acid in the inhibition of fibrinolysis. Raska A; Kálmán K; Egri B; Csikós P; Beinrohr L; Szabó L; Tenekedjiev K; Nikolova N; Longstaff C; Roberts I; Kolev K; Wohner N J Thromb Haemost; 2024 Mar; 22(3):794-804. PubMed ID: 38016517 [TBL] [Abstract][Full Text] [Related]
26. Tranexamic acid integrated into platelet-rich fibrin produces a robust and resilient antihemorrhagic biological agent: a human cohort study. Asher R; Oren F; Meir T; Shapira L; Assad R; Polak D Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Oct; 134(4):449-456. PubMed ID: 35718721 [TBL] [Abstract][Full Text] [Related]
27. Tranexamic acid loaded in a physically crosslinked trilaminate dressing for local hemorrhage control: Preparation, characterization, and in-vivo assessment using two different animal models. El Halawany M; Khashaba M; AbouGhaly MHH; Latif R Int J Pharm; 2024 Jun; 659():124219. PubMed ID: 38734277 [TBL] [Abstract][Full Text] [Related]
28. A new topical hemostatic agent TT-173 reduces blood loss in a sheep model of total knee arthroplasty. Centeno A; Rojas S; Arias B; Miquel I; Sánchez P; Ureta C; Rincón E; López R; Murat J Knee; 2017 Dec; 24(6):1454-1461. PubMed ID: 28865948 [TBL] [Abstract][Full Text] [Related]
29. Tranexamic acid (class I drug) reduced and capped gold nanoparticles as a potential hemostatic agent with enhanced performance. Jha CB; Singh C; Patil P; Manna K; Singh S; Varshney R; Mathur R Nanotechnology; 2023 Dec; 35(9):. PubMed ID: 37995371 [TBL] [Abstract][Full Text] [Related]
30. Regional hemostatic status and blood requirements after total knee arthroplasty with and without tranexamic acid or aprotinin. Engel JM; Hohaus T; Ruwoldt R; Menges T; Jürgensen I; Hempelmann G Anesth Analg; 2001 Mar; 92(3):775-80. PubMed ID: 11226117 [TBL] [Abstract][Full Text] [Related]
32. The effect of tourniquet application, tranexamic acid, and desmopressin on the procoagulant and fibrinolytic systems during total knee replacement. Ellis MH; Fredman B; Zohar E; Ifrach N; Jedeikin R J Clin Anesth; 2001 Nov; 13(7):509-13. PubMed ID: 11704449 [TBL] [Abstract][Full Text] [Related]
33. Polysaccharide-based (kappa carrageenan/carboxymethyl chitosan) nanofibrous membrane loaded with antifibrinolytic drug for rapid hemostasis- in vitro and in vivo evaluation. Salmasi SS; Ehsani M; Zandi M; Saeed M; Sabeti M Int J Biol Macromol; 2023 Aug; 247():125786. PubMed ID: 37451380 [TBL] [Abstract][Full Text] [Related]
34. Hyperfibrinolysis drives mechanical instabilities in a simulated model of trauma induced coagulopathy. Gosselin AR; White NJ; Bargoud CG; Hanna JS; Tutwiler V Thromb Res; 2022 Dec; 220():131-140. PubMed ID: 36347079 [TBL] [Abstract][Full Text] [Related]
35. Iota-carrageenan/xyloglucan/serine powders loaded with tranexamic acid for simultaneously hemostatic, antibacterial, and antioxidant performance. de Moraes FM; Philippi JV; Belle F; da Silva FS; Morisso FDP; Volz DR; Ziulkoski AL; Bobinski F; Zepon ΚM Biomater Adv; 2022 Jun; 137():212805. PubMed ID: 35929232 [TBL] [Abstract][Full Text] [Related]
36. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. Hvas AM; Sørensen HT; Norengaard L; Christiansen K; Ingerslev J; Sørensen B J Thromb Haemost; 2007 Dec; 5(12):2408-14. PubMed ID: 18034766 [TBL] [Abstract][Full Text] [Related]
37. Bacteriosynthetic Degradable Tranexamic Acid-Functionalized Short Fibers for Inhibiting Invisible Hemorrhage. Bao L; Zhang Z; Li X; Zhang L; Tian H; Zhao M; Ye T; Cui W Small; 2023 Nov; 19(47):e2303615. PubMed ID: 37501326 [TBL] [Abstract][Full Text] [Related]
38. Effects of intravenous administration of tranexamic acid on hematological, hemostatic, and thromboelastographic analytes in healthy adult dogs. Kelmer E; Segev G; Papashvilli V; Rahimi-Levene N; Bruchim Y; Aroch I; Klainbart S J Vet Emerg Crit Care (San Antonio); 2015; 25(4):495-501. PubMed ID: 26088425 [TBL] [Abstract][Full Text] [Related]
39. Injectable negatively charged gelatin microsphere-based gels as hemostatic agents for intracavitary and deep wound bleeding in surgery. Li L; Du Y; Xiong Y; Ding Z; Lv G; Li H; Liu T J Biomater Appl; 2018 Nov; 33(5):647-661. PubMed ID: 30335542 [TBL] [Abstract][Full Text] [Related]
40. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood. Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]